Tumor-intrinsic METTL3 suppresses CD8+ T cell activation and effector functions, thereby driving immune evasion and non-alcoholic fatty liver disease related hepatocellular carcinoma progression. This evidence concerns the gene METTL3 and hepatocellular carcinoma.